3 terminated, 2 completed, 1 active not recruiting, 1 unknown. 3 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Malignant Ovarian Brenner Tumor: new trials by email Literature Review of Malignant Ovarian Brenner Tumor trials Research Report on Malignant Ovarian Brenner Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors Exercise Counseling, Aerobic Exercise, Physiological Support - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Not applicable | Terminated | University of Washington | 64 | 2018-12-05 | 2023-11-29 |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2017-05-05 | 2024-03-13 |
| MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 34 | 2014-04-25 | 2026-08-24 |
| Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Behavioral Dietary Intervention, Compliance Monitoring, Counseling - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | Gynecologic Oncology Group | 1070 | 2012-06-18 | 2018-02-19 |
| First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Bevacizumab, Carboplatin, Paclitaxel - Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 33 | 2010-04-14 | 2022-10-28 |
| Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1560 | 2009-08-11 | 2026-06-02 |
| YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Terminated | Gynecologic Oncology Group | 2500 | 2007-09-01 | 2018-05-22 |
Brenner Tumor (7) · Fallopian Tube Neoplasms (5) · Ovarian Neoplasms (5)
Adnexal Diseases (7) · Endocrine System Diseases (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genital Diseases (7) · Genital Diseases, Female (7) · Genital Neoplasms, Female (7) · Gonadal Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms, Connective Tissue (7) · Neoplasms, Connective and Soft Tissue (7) · Neoplasms, Fibroepithelial (7) · Neoplasms, Fibrous Tissue (7) · Neoplasms, Glandular and Epithelial (7)
Bevacizumab (3) · Disulfides (3) · Immunoglobulin G (3) · Paclitaxel (3) · Taxes (3) · Carboplatin (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Cisplatin (1) · Counseling (1) · Early Intervention, Educational (1) · Educational Status (1) · Exercise (1) · Magnetic Resonance Spectroscopy (1) · Mesenchymal Stem Cell Transplantation (1) · Methods (1)
Gynecologic Oncology Group (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · University of Washington (1)
United States (7)
Anil K. Sood, MD (1) · Anil Sood (1) · David Alberts (1) · Evanthia Galanis, MD (1) · Joan L Walker (1) · Katherine Bell-McGuinn (1) · Kathryn Pennington (1)
PMID 27394382, PMID 31002578, PMID 36608382
U10CA027469 (2), U10CA180868 (2), P50CA136393 (1), R01CA136547 (1), R01CA200507 (1), R21CA215662 (1), U10CA101165 (1), U10CA180830 (1), UG1CA189867 (1)